Icosapent ethyl
ApprovedTerminated 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Covid19
Conditions
Covid19, Atherosclerosis, Cardiovascular Diseases, Upper Respiratory Tract Infections
Trial Timeline
Aug 7, 2020 โ Dec 15, 2022
NCT ID
NCT04505098About Icosapent ethyl
Icosapent ethyl is a approved stage product being developed by Amarin Corporation for Covid19. The current trial status is terminated. This product is registered under clinical trial identifier NCT04505098. Target conditions include Covid19, Atherosclerosis, Cardiovascular Diseases.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04505098 | Approved | Terminated |
| NCT04412018 | Phase 2 | Completed |
Competing Products
20 competing products in Covid19